Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Cleve Clin J Med ; 81(6): 367-72, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24891538

ABSTRACT

Prescribing in pregnancy can be challenging for providers facing insufficient information about drug safety, overestimation of the risk of medications by both the patient and the care provider, and increasing litigation costs. This article provides key concepts to consider when prescribing for a pregnant patient and offers practical advice for choosing the safest possible drug treatments.


Subject(s)
Abnormalities, Drug-Induced/prevention & control , Drug Therapy , Drug-Related Side Effects and Adverse Reactions/prevention & control , Maternal-Fetal Exchange/drug effects , Female , Fetal Development/drug effects , Gestational Age , Humans , Maternal-Fetal Exchange/physiology , Pregnancy , United States , United States Food and Drug Administration/standards
2.
Thromb Res ; 123(3): 550-5, 2009.
Article in English | MEDLINE | ID: mdl-18706683

ABSTRACT

INTRODUCTION: Venous thromboembolism (VTE) is one of the leading causes of maternal mortality in the United States. Cesarean delivery is a known risk factor. This study was to determine the incidence of deep vein thrombosis (DVT) post cesarean delivery. MATERIALS AND METHODS: This was a prospective cohort study where two patients having undergone cesarean delivery each day were randomly selected. A lower extremity compression ultrasound was performed prior to hospital discharge. If no DVT was detected, participants were asked to return for a second ultrasound two weeks postpartum. Participants were also telephone-interviewed at three months for reported VTE. RESULTS: Of the 194 patients who consented to study participation, only one participant developed DVT after cesarean delivery, giving an overall incidence of 0.5% (95% CI, 0.1 to 2.8%). There were no DVT identified on the second ultrasound nor VTE reported 3 months postpartum. CONCLUSIONS: We found the DVT rate after cesarean delivery to be 0.5%.


Subject(s)
Cesarean Section/adverse effects , Postoperative Complications/etiology , Venous Thrombosis/etiology , Adolescent , Adult , Cohort Studies , Female , Humans , Postoperative Complications/diagnostic imaging , Postoperative Complications/epidemiology , Pregnancy , Prospective Studies , Puerperal Disorders/diagnostic imaging , Puerperal Disorders/epidemiology , Puerperal Disorders/etiology , Risk Factors , Ultrasonography , Venous Thrombosis/diagnostic imaging , Venous Thrombosis/epidemiology , Young Adult
3.
Obstet Med ; 1(1): 18-23, 2008 Sep.
Article in English | MEDLINE | ID: mdl-27630741

ABSTRACT

OBJECTIVE: The aim of this study is to assess the diagnostic accuracy of the spot urine protein/creatinine ratio compared with the 24-hour urine protein in pregnancy. STUDY DESIGN: In this prospective cohort study of inpatient pregnant women, the protein/creatinine ratio and dipstick protein were assessed from a single urine sample collected at the start of the 24-hour urine. Both tests were compared with the 24-hour urine protein for correlation and test characteristics. RESULTS: In the 196 specimens analysed, we found a strong correlation between the spot urine protein/creatinine ratio and 24-hour urine protein (r (2) = 0.78, P < 0.01). A protein/creatinine ratio <0.1 ruled out significant proteinuria (≥300 mg/day) with sensitivity and negative predictive value 100%. A protein/creatinine ratio ≥0.4 detected significant proteinuria (specificity and positive predictive value of 100%). A protein/creatinine ratio ≥4.6 had a specificity and positive predictive value of 100% for detecting severe proteinuria (≥5000 mg/day). Urine dipsticks correlated poorly with the 24-hour urine protein (r (2) = 0.40, P = 0.826). Nineteen percent of dipsticks reading nil or trace were false-negative results. CONCLUSION: The spot urine protein/creatinine ratio correlated well with the 24-hour urine protein and performed better than the urine dipsticks. Significant proteinuria in pregnancy was excluded if the protein/creatinine ratio was <0.1 and identified when it was ≥0.4.

4.
Obstet Med ; 1(1): 11-7, 2008 Sep.
Article in English | MEDLINE | ID: mdl-27630740

ABSTRACT

OBJECTIVE: This study was undertaken to evaluate whether or not an educational pamphlet could improve knowledge without increasing anxiety in women with preeclampsia. METHODS: One hundred women recruited from an inpatient setting with suspected or proven preeclampsia were asked to answer a questionnaire assessing demographics, knowledge (primary outcome), anxiety and satisfaction (secondary outcomes) after being randomized to an intervention group (who received a pamphlet) or a control group (who did not received a pamphlet). The pamphlet and questionnaire, both designed by a multidisciplinary team, were read and answered at the same time. RESULTS: Baseline and demographic characteristics were similar between the two groups. Knowledge about the symptoms of pre-eclampsia was excellent in both groups (61% to 100% correct answers). Women in both groups were well aware that preeclampsia in the past (P = 0.22) and a family history of preeclampsia (P = 0.57) were risk factors. There was a significant difference in knowledge about the risk of some fetal complications, including death (90% versus 39%, P < 0.01) and all maternal complications (P < 0.05) favouring the intervention group. Despite increased knowledge about preeclampsia and its risks, anxiety was not greater in the intervention group. Overall, there was a trend towards less knowledge in vulnerable subgroups (non-white, low income and schooling levels), but the improvement of knowledge with the pamphlet was equivalent. Baseline anxiety was higher in the vulnerable groups, but was generally not increased by the pamphlet. CONCLUSION: An educational pamphlet for women with suspected preeclampsia was able to increase knowledge without increasing anxiety.

5.
JAMA ; 298(13): 1548-58, 2007 Oct 03.
Article in English | MEDLINE | ID: mdl-17911500

ABSTRACT

Mrs F is a 30-year-old woman with a history of chronic hypertension and possible preeclampsia during her first pregnancy. She is currently trying to conceive and wants to know how her hypertension will affect a future pregnancy and how it should best be managed, both now and during a pregnancy. The management of chronic hypertension before, during, and after a pregnancy is discussed with an emphasis on the goals of treatment and safety of medications during pregnancy and with breastfeeding. Preeclampsia is the most common complication of chronic hypertension in pregnancy and is a particular worry for Mrs F because she may have had it with her prior pregnancy. The current understanding of the pathogenesis of this enigmatic illness is therefore also reviewed, along with its implications for long-term maternal health.


Subject(s)
Hypertension/prevention & control , Pre-Eclampsia/prevention & control , Preconception Care , Adult , Antihypertensive Agents/therapeutic use , Breast Feeding , Chronic Disease , Female , Humans , Hypertension/physiopathology , Infertility, Female , Insemination, Artificial , Lactation/drug effects , Postpartum Period , Pregnancy , Risk Assessment , Risk Reduction Behavior
6.
Treat Respir Med ; 5(1): 1-10, 2006.
Article in English | MEDLINE | ID: mdl-16409012

ABSTRACT

Pregnancy does not appear to have a consistent effect on the frequency or severity of asthma. The most common cause of worsening asthma in pregnancy is likely to be noncompliance with medication. Emphasizing to the patient in advance that fetal well-being is dependent on maternal well-being may help prevent this.In general, well controlled asthma is not associated with a higher risk of adverse pregnancy outcomes. Essential to successful asthma management is patient education that helps to ensure effective medication use, avoidance of triggers, and prompt treatment. This education should include measurement of peak expiratory flow rate and a written asthma action plan. Most of the medications that are used to control asthma in the general population can be safely used in pregnant women. Inhaled beta-adrenoceptor agonists (beta-agonists), cromolyn sodium (sodium cromoglycate), and inhaled and systemic corticosteroids all appear to be very well tolerated by the fetus. Budesonide and beclomethasone should be considered as the preferred inhaled corticosteroids for the treatment of asthma in pregnancy. Use of the leukotriene receptor antagonists zafirlukast and montelukast in pregnancy is probably safe but should be limited to special circumstances, where they are viewed essential for asthma control. Zileuton should not be used in pregnancy.Acute asthma exacerbations in pregnant women should be treated in a similar manner to that in non-pregnant patients. Maternal blood glucose levels should be monitored periodically in pregnant women receiving systemic corticosteroids because of the deleterious effects of hyperglycemia upon embryos and fetuses. During pregnancy, maternal arterial oxygen saturations should be kept above 95% if possible for fetal well-being. Ambulatory oxygenation should be checked prior to discharge to ensure that women do not desaturate with their daily activities.Acute exacerbations of asthma during labor and delivery are rare. Dinoprost, ergometrine, and other ergot derivatives can cause severe bronchospasm, especially when used in combination with general anesthesia, and should be avoided in asthmatic patients. Pregnant women who have been treated with corticosteroids in the past year may require stress-dose corticosteroids during labor and delivery. Most asthma medications, including oral prednisone, are considered compatible with breast-feeding.


Subject(s)
Anti-Asthmatic Agents , Asthma , Adrenal Cortex Hormones/administration & dosage , Anti-Asthmatic Agents/administration & dosage , Asthma/drug therapy , Cromolyn Sodium/therapeutic use , Humans , Leukotriene Antagonists/therapeutic use , Mothers
SELECTION OF CITATIONS
SEARCH DETAIL